Medicinal cannabis hub
Information about access pathways for medicinal cannabis products.
Last updated
The medicinal cannabis hub provides information on the regulation of medicinal cannabis in Australia along with guidance material and information resources for individuals and patients, health professionals, and sponsors.
Most medicinal cannabis goods are unapproved goods. Unapproved goods have not been assessed by us for safety, quality, performance or effectiveness.
Where clinically appropriate, there are pathways for registered health professionals to access unapproved medicinal cannabis goods for their patients.
The 2024 vaping reforms resulted in some changes to the regulation of vaping devices that are intended to be used to vape medicinal cannabis.
More information
- Process to include a medicinal cannabis vaping device or cannabis device accessory on the ARTG
- Applications and reporting
- Medicinal cannabis products by active ingredients
- Resources, clinical trials and clinical evidence
- Presentation: TGO93 testing and regulation of medicinal cannabis
- Medicinal cannabis - guidance documents
Frequently asked questions
- Access to medicinal cannabis products
- Accessing medicinal cannabis for a patient
- Importation, manufacture and supply of unapproved medicinal cannabis products
Data
Reforms
- Webinar presentation: Medicinal cannabis - Changes to Special Access Scheme (SAS) and Authorised Prescriber applications, 22 November 2021
- Webinar presentation: Medicinal cannabis - Changes to sponsor requirements for supplying unapproved medicinal cannabis products in Australia, 22 November 2021
- Webinar presentation: Medicinal cannabis - Changes to Special Access Scheme (SAS) and Authorised Prescriber applications, 23 November 2021
- Webinar: Medicinal cannabis reforms
Latest articles
-
Atlus, Mamamia and News Life Media face court for alleged unlawful advertising of medicinal cannabis
We have commenced proceedings in the Federal Court of Australia against Atlus and its sole director, Mamamia, News Life and Straight Up for advertising medicinal cannabis in alleged contravention of the Therapeutic Goods Act 1989. -
Summit Pharmacy Pty Ltd issued infringement notices for the alleged unlawful manufacturing of medicinal cannabis products
We have issued 4 infringement notices totalling $75,120 to Queensland based pharmacy Summit Pharmacy Pty Ltd, for the alleged unlawful manufacturing of medicinal cannabis products. -
News Life Media fined for alleged unlawful advertising of medicinal cannabis
TGA has issued 3 infringement notices totalling $56,340 to News Life Media Pty Ltd for alleged unlawful advertising of medicinal cannabis on their popular lifestyle website Body+Soul.
Latest publications
-
Clarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).
-
Medicinal cannabis products are permitted to be supplied into Australia under the Special Access Scheme, by authorised prescribers, and/or for use in clinical trials.
-
This publication outlines our plan to transition to a paperless model for Special Access Scheme (SAS) and Authorised Prescriber (AP) submissions. From 1 July 2024 we will only accept submissions via the SAS/AP Online System.